Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses.

Pattinson, David; Jester, Peter; Gu, Chunyang; Guan, Lizheng; Armbrust, Tammy; Petrie, Joshua G; King, Jennifer P; Nguyen, Huong Q et al. · EBioMedicine · 2024

prospective_cohort · Level II

Where this comes from

Abstract

World Health Organisation (WHO) and USA Centers for Disease Control and Prevention (U.S. CDC) recommendations now allow simultaneous administration of COVID-19 and other vaccines. We compared antibody responses after coadministration of influenza and bivalent COVID-19 vaccines in the same (ipsilateral) arm vs. different (contralateral) arms. Pre- and post-vaccination serum samples from individuals in the Prospective Assessment of COVID-19 in a Community (PACC) cohort were used to conduct haemaglutination inhibition (HI) assays with the viruses in the 2022-2023 seasonal influenza vaccine and focus reduction neutralisation tests (FRNT) using a BA.5 SARS-CoV-2 virus. The effect of ipsilateral vs. contralateral vaccination on immune responses was inferred in a model that accounted for higher variance in vaccine responses at lower pre-vaccination titers. Ipsilateral vaccination did not cause higher influenza vaccine responses compared to contralateral vaccination. The response to SARS-CoV-2 was slightly increased in the ipsilateral group, but equivalence was not excluded. Coadministration of influenza and bivalent COVID-19 vaccines in the same arm or different arms did not strongly influence the antibody response to either vaccine. This work was supported by the U.S. CDC (grant number: 75D30120C09259).

Medical subject headings